Skip to main content
Premium Trial:

Request an Annual Quote

Underwriters Partially Exercise Overallotment Option on Cancer Genetics' Public Offering

NEW YORK (GenomeWeb News) – Cancer Genetics today said that the underwriters for its recent public offering have partially exercised an overallotment option, purchasing an additional 105,000 shares at $10 per share.

As a result, the gross proceeds from the offering increased to about $16.1 million.

The Rutherford, NJ-based cancer diagnostics firm closed on the offering last month, and said that net proceeds would go toward expanding its sales and marketing operations; further commercializing products; investing in its joint venture with Mayo Clinic called OncoSpire; retiring mezzanine financing; and funding R&D and other general working capital needs.

Aegis Capital was the sole book-running manager for the offering, and Feltl and Co., was the co-lead manager. Cancer Genetics had granted the underwriters a 45-day option to purchase up to 225,000 additional shares of its common stock to cover any overallotments.

The Scan

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.

Active Lifestyle Linked to Type 2 Diabetes Prevention in People at High Genetic Risk

A study in the British Journal of Sports Medicine shows that an active lifestyle goes a long way in type 2 diabetes prevention.

Beneficial, Harmful Effects of Introgression Between Wild and Domesticated European Grapes

A paper in PNAS shows that European wild grapevines were an important resource for improving the flavor of cultivated wine grapes.

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.